CIK细胞对晚期非小细胞肺癌预后的影响  

The Prognostic Analysis of the Therapeutics of Cytokine induced Killer Cells on the Patients with Advanced Non Small Cell Lung Cancer

作　　者：方慧云[1] 程伟民[1] 李晓玲[1] 季明芳[1] 

机构地区：[1]中山市人民医院肿瘤研究所,528403

出　　处：《实用癌症杂志》2011年第6期573-574,共2页The Practical Journal of Cancer

摘　　要：目的观察细胞因子诱导的杀伤细胞(CIK细胞)体外培养后,对晚期非小细胞肺癌的疗效。方法收集经确诊的、并发生转移、且采用标准治疗方案的非小细胞肺癌患者20例作为观察组,取外周血分离单个核细胞(PBMC),体外细胞因子诱导培养CIK细胞,流式细胞仪检测细胞表型。20例患者均接受CIK细胞免疫治疗,观察其免疫活性及生存期。并以20例采用标准治疗方案而未经CIK治疗的晚期非小细胞肺癌患者作为对照组。结果观察组培养后的细胞表型CD3、CD3+CD56+明显升高,生存期为(16.15±3.8)个月,对照组生存期为(9.12±3.2)个月。结论经CIK细胞治疗后晚期非小细胞肺癌患者的生存期明显延长。Objective It is to investigate the cytotoxicity in vitro of cytokine-induced killer（CIK） cells after coculturing,and to observe their clinical antitumour efficacy,immunological activity.Methods Peripheral blood mononuclear cells（PBMC） were isolated from 20 patients with advanced non small cell lung cancer,who had been treated with standard protocol.CIK cells were induced and coculture in vitro.The phenotypes changes of CIK cells were identified by flow cytometric analysis.20 patients were treated with CIK cells for immunotherapy,and we evaluated their clinical antitumour efficacy,immunological activity and survival instances of them.Results The survival of the experiment group was（16.15±3.8）months,while the other group was（9.12±3.2）months,which was statistically significantly different（P 0.05）.Conclusion CIK is effective to advanced non small cell lung cancer and it can imp rove the prognosis of them.

关 键 词：细胞因子诱导的杀伤细胞 非小细胞肺癌 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]